Objectives: Symptoms of eosinophilic esophagitis are variable and can be nonspecific. Food-specific serum immunoglobulin E (IgE) antibodies are frequently found in patients with eosinophilic esophagitis and are obtained using a widely available blood test. Our objective was to evaluate the ability of food-specific IgE antibodies to predict the presence of esophageal eosinophilia. Methods: We reviewed 144 medical records for pediatric patients having esophageal biopsy and serum analysis for IgE antibodies to food (exploratory group). We performed logistic regression using sex and number of positive food-specific IgE tests to develop a model that predicts !15 eosinophils/high-power field (hpf) in the esophagus. We tested the model using 142 additional patients (validation group). Results: The probability of having !15 eosinophils/hpf in the esophagus was higher in boys and increased with the number of positive food-specific IgE tests from 12% (95% confidence interval 4.8-26) in girls with 0 foods positive to 86% (95% confidence interval 71-94) for boys with 4 or 5 foods positive. The statistical model using sex and number of positive IgE tests to predict patients having !15 eosinophils/hpf showed acceptable discriminative ability (area under the receiver operating characteristic curve 0.80). The performance metrics for the model to predict !15 eosinophils/hpf in the validation group were similar (area under the receiver operating characteristic curve 0.75). Conclusions: Requiring only a blood test and a simple algorithm, analysis for IgE antibodies to food may expedite an esophagogastroduodenoscopy and decrease delays in the diagnosis and treatment of patients with nonspecific gastrointestinal symptoms who have increased eosinophils in the esophagus.
The probability of having esophageal eosinophilia is increased in patients who have immunoglobulin E antibodies to multiple foods. Analysis for immunoglobulin E antibodies to food in patients with nonspecific gastrointestinal symptoms may decrease delays in diagnosis and treatment of esophageal eosinophilia. E osinophilic esophagitis (EoE) is an increasingly recognized disease process with recently reported prevalence estimates ranging from 0.05% to 0.1% in the general population (1) . In a 2011 expert consensus document, EoE was defined as a ''chronic, immune/antigen-mediated esophageal disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation'' (2) . In that updated consensus document with expert recommendations, esophagogastroduodenoscopy (EGD) with esophageal biopsy showing at least 15 eosinophils per high-power field (hpf) was reaffirmed as the criterion standard for diagnosis (2, 3) . Although symptoms have been described in many different cohorts, the clinical picture is heterogeneous and includes failure to thrive, food aversion, regurgitation or vomiting, dysphagia, and food impaction (4) (5) (6) (7) . In some patients, cough that fails to respond to medical treatment is the predominant presenting symptom (8) . Furthermore recent studies have suggested that the risk of esophageal stricture increases with the duration of untreated eosinophilic inflammation (9, 10) . Given the variation in presenting symptoms and the increased morbidity associated with delayed treatment, a specific screening test to predict the presence of eosinophils and expedite an esophageal biopsy would be useful.
Food antigens seem to be the primary cause of EoE in combination with recently recognized genetic predisposition and environmental factors (11, 12) . Cow's milk is a common causal food, and wheat, egg, and soy are also frequently offending foods (13) (14) (15) . Low levels of immunoglobulin E (IgE) antibodies to milk and other foods are a remarkably common finding in patients with EoE and are often found even when skin prick tests are negative (16) (17) (18) . In spite of having IgE antibodies, most patients with EoE do not experience typical symptoms of an IgE-mediated reaction (ie, hives or angioedema). High levels of IgG4 antibodies to food have also been reported (19) . The role of IgE and IgG4 antibodies in EoE is not yet clear. We have recently observed that patients with very low or undetectable IgE antibodies to milk can respond to treatment with cow's milk elimination diet (20) . Taken with evidence that EoE does not respond to treatment with anti-IgE, our previous results suggest that IgE antibodies are a marker of an inflammatory response to food but not the cause of the disease process (18, 19) .
Serological methods to measure IgE antibodies are analytically sensitive, easily performed, widely available, and are not subject to interobserver variation (21) . Traditionally IgE levels have been used with a patient's history to obtain information about clinical relevance at baseline and monitored over time to make decisions about possible food reintroduction (22) . The objective of the present study was to evaluate the feasibility of using the presence of low levels of IgE to multiple foods in patients who have gastrointestinal symptoms as a biomarker to predict having !15 eosinophils/hpf in the esophagus.
METHODS
Medical records were reviewed for pediatric patients having both serum analysis for IgE antibodies to food by ImmunoCAP and EGD with esophageal biopsy for any reason at Nationwide Children's Hospital (Columbus, OH) between April and September of 2015 (n ¼ 144). These patients were designated the ''exploratory'' subset. Clinical data collected by chart review included demographics, symptoms, peripheral blood eosinophil counts, esophageal biopsy results, and levels of IgE antibodies to 5 foods that are most commonly implicated as causative for EoE (ie, milk, egg, wheat, soy, and peanut). As a ''validation'' sample, the same data were collected from medical records of pediatric patients having EGD with esophageal biopsy between January and June of 2009 and between January and June of 2012 (n ¼ 174). All charts were reviewed by 3 medically trained professionals (E.A.E., M.R., J.B.L.). The present study was approved by the institutional review board at Nationwide Children's Hospital.
A logistic regression model (Model 1) was estimated on the exploratory dataset. The outcome of interest was a binary indicator of whether the patient showed !15 eosinophils/hpf on the current, or any prior, esophageal biopsy. Given that EoE is generally thought to be chronic, a prior esophageal biopsy with !15 eosinophils/hpf was considered an indicator of previous diagnosis of esophageal eosinophilia. We excluded patients with inflammatory bowel disease from the analysis. Those with proton pump inhibitor (PPI)-responsive esophageal eosinophilia were not excluded because they typically have similar clinical, endoscopic, and genetic features when compared with patients with EoE (23) . Explanatory variables in the model included the binary variable sex and a categorical variable for having detectable IgE antibodies !0.10 IU/mL (ie, a positive test by ImmunoCAP analysis) to the foods milk, egg, wheat, soy, or peanut. Only unique patients who were tested for all 5 foods were included (n ¼ 119). The presence of IgE antibodies to food was coded using 3 different levels: 0 foods positive, 1 to 3 foods positive, and 4 or 5 foods positive (see Supplemental Digital Content 1, http://links.lww.com/MPG/A919, for details relating to IgE testing and additional potential variables that were considered for the model).
The model performance metrics, including area under the receiver operating characteristic (ROC) curve (c-statistic), sensitivity, specificity, positive likelihood ratio (LR), and negative LR, were estimated. LRs were calculated to estimate the usefulness of the model for predicting the probability of disease independent of its prevalence. We assessed the prediction and discrimination characteristics of Model 1 using the validation dataset. After validation, we re-estimated the model on the combined data (exploratory and validation datasets) to provide readers with a table that shows the predicted probability of finding !15 eosinophils/hpf for male and female patients based on the number of positive IgE tests. Statistical analyses were performed using Stata 14 (StataCorp, College Station, TX).
As we studied the model, it seemed that it would be especially useful to be able to predict esophageal eosinophilia in patients who have nonspecific symptoms. To focus on this group, we excluded patients who reported food impactions and dysphagia and developed a model (Model 2) using the variables gender and number of positive IgE tests as explained previously (Supplemental Digital Content 2, Table S1 , http://links.lww.com/MPG/A920). We calculated the model performance metrics as a measure of the utility of serum IgE results in this group.
(See Supplemental Digital Content 1, http://links.lww.com/ MPG/A919, for Model 3-examining a lower threshold for eosinophil counts.)
RESULTS

Exploratory and Validation Patient Subsets
The prevalence of esophageal eosinophilia in patients having EGD was significantly higher in the exploratory subset from 2015 as compared with the historical, validation subset from 2009 and 2012 (Table 1) . As expected, detectable IgE antibodies (ie, >0.10 IU/mL) to food were common among patients with eosinophils infiltrating the esophagus. The proportion of patients with !15 eosinophils/hpf who also had a low level of IgE antibodies to at least 1 food was 85% in both datasets as compared with 44% (exploratory group) and 46% (validation group) in patients with <15 eosinophils/hpf (P < 0.001 for each group). In the ''exploratory'' dataset, milk was the most common food sensitization (78%) for patients with esophageal eosinophilia followed in frequency by wheat (69%), egg (64%), peanut (54%), and soy (53%) ( Table 2) . These proportions were similar among the patients with !15 eosinophils/ hpf in the validation group. Detectable IgE antibodies were significantly more common in patients with !15 eosinophils/hpf compared with patients with <15 eosinophils/hpf for nearly every food tested (Table 2) .
Exploratory Model
Patients who were tested for IgE antibodies to all 5 foods (ie, milk, egg, wheat, soy, and peanut) (n ¼ 119) were included in the ''exploratory'' dataset used to develop the model to predict the outcome of !15 eosinophils/hpf on esophageal biopsy. The probability of having !15 eosinophils/hpf on esophageal biopsy increased with the number of foods with positive IgE results. The predicted probability of having !15 eosinophils/hpf ranged from 12% (95% confidence interval [CI] 4.8-26) for girls without detectable IgE antibodies to food to 86% (95% CI 71-94) for boys with 4 or 5 positive foods. Of note, the probability of having !15 eosinophils/hpf was higher for boys compared with girls at each level of having IgE to foods. Given the sex differences, we analyzed girls separately in relation to age and symptoms to determine whether additional variables improved the model. We did find a significant interaction between female sex and vomiting (P ¼ 0.05) suggesting that vomiting has one effect on the model for boys and a different effect for girls. Including the interaction, however, did not improve the model, so we continued by fitting the model without the interaction.
When we measured the performance of the model (Model 1) on the exploratory dataset, it was able to correctly predict esophageal biopsy results 75% of the time. Sensitivity and specificity of the model were 78% and 72%, respectively ( Table 3 ). The positive LR was 2.75 (95% CI 1.80-4.21) and the negative LR was 0.31 (95% CI 0.19-0.51). The area under the ROC curve (c-statistic) was 80% (Fig. 1A) . A nonsignificant Hosmer-Lemeshow goodness-offit P value of 0.5 suggests that the model fits the data.
Validation Testing
We tested Model 1 using patients in the validation group who had IgE antibody results for all 5 foods (n ¼ 142). To classify model performance, patients with probability !50% were considered to be predicted to have !15 eosinophils/hpf. The performance metrics were similar when the model was applied to the observations from 2009 and 2012. In this separate group of patients, the sensitivity was 76% and specificity 69% ( Table 3 ). The positive LR was 2.44 (95% CI 1.74-3.43) and the negative LR was 0.35 (95% CI 0.21-0.60). The area under the ROC curve was 75% (Fig. 1B) . The proportion correctly classified was in the acceptable range of discrimination ability at 71 (24) .
Cases That Were Incorrectly Classified by Model 1
Overall 25% of patients were incorrectly classified by using Model 1. When the model was applied to the combined exploratory and validation datasets (n ¼ 261), 30 patients were not predicted to have increased esophageal eosinophils but had a biopsy with !15 eosinophils/hpf. This group of patients was classified as having a false negative test. The proportion of male (n ¼
In contrast, 51 patients were classified as having a false positive test. Using the predictive model, these patients were more likely than not to have increased eosinophils in the esophagus, but their biopsies yielded <15 eosinophils/hpf. The majority of these patients were boys (87%). No eosinophils were noted in 33 of 51 (65%) and 1 to 14 eosinophils were reported in 18 of 51 (35%). A proportion (33/51) were on PPI before having esophageal biopsy performed, and some of these patients may have responded resulting in a biopsy with <15 eosinophils/hpf. In addition, there was a small group of patients (n ¼ 4) avoiding foods with milk before the biopsy. We do not know whether they had a negative biopsy because of dietary ''treatment.''
Model 2-Patients Without Food Impaction or Dysphagia
A proportion of our patients with esophageal eosinophilia (44/104) presented with symptoms other than food impaction and dysphagia (Table 4) . When we developed a model that included only these patients, we found that the number of positive IgE tests yielded the same predictions as Model 1 (Supplemental Digital 
DISCUSSION
Similar to reports from other groups, the finding of eosinophils in the esophagus is increasing over time at our institution. A screening test to identify patients who may need esophageal biopsy would be helpful due to the heterogeneous nature of the symptoms and the increase in esophageal strictures associated with delays in treatment of eosinophilic inflammation (9, 10) . Levels of IgE antibodies are a common finding in patients with EoE, and we have recently proposed that they may be a marker of causal foods and have some utility in planning dietary treatment (18, 20) . The present study suggests a new role for serum analysis for IgE antibodies. In patients with symptoms for which an EGD is a consideration, serum IgE antibodies to food may be used as a noninvasive biomarker to calculate the probability of having !15 eosinophils/hpf on biopsy with moderate sensitivity and specificity and satisfactory positive and negative LR. Incorporating the results of such a model in the evaluation of patients could be helpful in the diagnosis of the complex disease processes that involve esophageal eosinophilia.
Our model to predict the presence of 15 or more eosinophils/ hpf in the esophagus (labeled Model 1) is simple. With the variables sex and serum IgE levels to milk, egg, wheat, soy, and peanut, the probability of a patient having esophageal eosinophilia can be determined by consulting a table (Fig. 2) . A patient with predicted probability !50% would be classified as more likely than not to have EoE. Our model can be described as moderately predictive based on its statistical performance characteristics (24) (25) (26) . The clinical value of a predictive test, however, depends on how it will be used (ie, diagnosis or screening) and the patient population for which it is intended. We propose that measurement of serum IgE levels be considered in patients who present for gastrointestinal evaluation to obtain information about eosinophils in the esophagus before performing a biopsy and to minimize delays in diagnosis and treatment of esophageal eosinophilia.
We are not proposing that this predictive score would apply to the general population. We are suggesting that it could be useful for patients who have gastrointestinal symptoms. Patients presenting for gastrointestinal evaluation may be classified as moderate risk or high risk for esophageal eosinophilia depending on the nature of their symptoms. Patients with classic EoE symptoms of dysphagia or food impaction would be considered high risk. Those with nonspecific symptoms such as abdominal pain, failure to thrive, or severe gastroesophageal reflux would be considered to have ''moderate risk.'' It is for this group with ''moderate risk'' that the serologic test may be most valuable. We have identified such patients whose diagnosis has been delayed for several years. A patient with nonspecific symptoms who had a positive predictive test would be twice as likely to have esophageal eosinophilia compared with someone who did not have a positive test. A predictive model also raises the question of whether other populations who are at increased risk compared with the general ROC ¼ receiver operating characteristic. population should be screened. This group would include siblings or family members of patients with EoE in whom an increased prevalence ranging from 2% to 10% has been reported (10, 27) . Patients with connective tissue disorders including Marfan syndrome, Loeys-Dietz syndrome, and Ehlers-Danlos syndrome, who also have an increased risk of EoE, would also be potential candidates for the screening test before performing EGD (28, 29) . Celiac disease, another gastrointestinal condition requiring EGD for diagnosis, provides a model for using a serologic assay for preliminary information. In most patients with celiac disease, IgA autoantibodies to tissue transglutaminase can be detected (30, 31) . These results are used with pathology findings to increase the detection rate and/or minimize the delay in diagnosis of celiac disease (32) . Although the demonstration of villous atrophy in duodenal biopsy is considered the criterion standard, biopsy results are graded histologically based on the Marsh criteria. The clinical significance of early changes may not be clear without serological results (32) . For a patient with nonspecific symptoms or risk factors that are associated with celiac disease, serologic testing can also be helpful (33, 34) . Comparison of groups of patients diagnosed with celiac disease before and after the use of serologic testing has revealed a ''new'' subgroup of patients who are less symptomatic based on nutritional status, growth measures, and tissue abnormalities noted on pathologic examination (33, 34) .
A variety of methods are available for serum IgE testing. Biochip technologies such as immune solid-phase allergen chip assays that measure IgE antibodies to a single protein have become increasingly available and utilized. It is important to note that these technologies cannot be used to detect IgE antibodies to food or to plan dietary treatment in patients with EoE (35, 36) . This is likely due to high levels of IgG4 antibodies to food in patients with EoE. As such, component-resolved diagnostic testing by immune solid-phase allergen chip would not be interchangeable with measurement of IgE antibodies to allergenic extracts (or components) using ImmunoCAP analysis for the purposes of predicting esophageal eosinophilia.
Our study has several limitations. Over the last decade, a major point of confusion in interpretation of eosinophilic inflammation in the esophagus has been the existence of a subgroup of patients who respond to PPI. Because of concerns about multiple endoscopies, some pediatric experts started treating patients who had suspicious symptoms with PPI before performing the first EGD, and this practice even seemed to be endorsed in pediatric guidelines (37) . This affects our study in 2 ways. First, we were unable to specifically define patients with PPI-responsive esophageal eosinophilia to analyze them separately. Second in keeping with this practice, some of our patients may have had a negative esophageal biopsy after treatment with PPI, but a predicted probability !50%. These patients would be classified as false positives, and they would lower the specificity of the model. Because of similar clinical, endoscopic, and genetic features and recent case series suggesting that individual patients can be responsive to both PPI and other dietary and medical treatments for EoE; it has been proposed that PPI simply be considered as a treatment option for esophageal eosinophilia (20, 38) . It is not yet clear, how this proposal will be incorporated into clinical practice. As a next step, our model will need to be tested in additional patients. Our results suggest that the predictive model may be even more helpful if patients have an EGD before starting a PPI. Another obvious challenge for this model is that there is a known subgroup of patients with EoE who are not atopic. As such, there were no detectable IgE antibodies for 16 of 104 (15%) of the patients with increased esophageal eosinophils in the present study. In contrast in a separate group of patients with EoE, we have recently measured high levels of IgG4 antibodies to milk proteins in 97% of those tested (39) . Further testing of a model that Values given in parentheses are 95% confidence intervals. A predicted probability of >50% suggests that the patient is more likely than not to have esophageal eosinophilia. hpf ¼ high-power field; IgE ¼ immunoglobulin E.
includes IgE and IgG4 antibodies to predict esophageal eosinophilia would be the next step.
In conclusion, screening tests are useful tools for predicting disease outcomes in groups of patients. This is especially true when symptoms can be nonspecific and a timely diagnosis is important to prevent future complications. In our study, the finding of an objective blood test and the resulting ease of use of the predictive model make analysis for IgE antibodies to food a practical and useful tool to be considered in the evaluation of patients with nonspecific gastrointestinal symptoms who may have eosinophils in the esophagus.
